Sep 07,2021

Indigo Diabetes Receives €3 million Hephaestus Research Grant to Support Development of CMM Technology

Indigo Diabetes N.V., a pioneering developer of medical solutions using nanophotonics, is pleased to announce that it has received a €3 million grant from VLAIO, the Flanders organisation for Innovation & Entrepreneurship, to conduct research into high volume production of its next-generation continuous multi-metabolite (CMM) technology.

FUNDING
View Analyst & Ambassador Comments
Go to original news
Sep 07,2021

Brighter is notified that its distributors in Nigeria and Ghana wish to renegotiate the distribution agreements - estimated revenues will either be substantially reduced or not materialise.

Brighter AB, today announced that it has received notice from the company’s distribution partners Wssonlines Nigeria Ltd in Nigeria and Fretac Plus Ventures in Ghana (“the Distributors”) that they wish to renegotiate the distribution contracts in Nigeria and Ghana covering Actiste® and Actiste® Mini (“Actiste® Service”), which was originally announced on 30 December 2020. It is now anticipated by the Company that the estimated revenues from such distribution agreements (stated below) will either not materialise or will be substantially reduced.

PRODUCT

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

DarioHealth Chosen by Northeast Regional Employer

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into an agreement to provide its suite of digital therapeutics for diabetes, hypertension and pre-diabetes to a Northeast regional employer ("Employer"). The contract is expected to contribute revenue beginning in the first quarter of 2022.

View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

Senseonics to Participate in the H.C. Wainwright Global Investment Conference

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Investment Conference.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

Liva Healthcare wins Healthy Hub eHealth competition and gets access to innovative partnerships with German sick funds

On Tuesday, April 1st, 2021, Healthy Hub called in for innovators in the German eHealth sector. More than 100 digital health companies applied for the third Healthy Hub competition, and only 15 eHealth providers made it through to the live pitches.

View Analyst & Ambassador Comments
Go to original news
Sep 12,2021

Oviva named to the 2021 CB Insights Digital Health 150 list of most innovative digital health startups

CB Insights yesterday named Oviva to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event.

View Analyst & Ambassador Comments
Go to original news
Sep 13,2021

Senseonics Announces a Collaboration with the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio

Senseonics Holdings, Inc. and Ascensia Diabetes Care, the makers of the CONTOUR® family of diabetes blood glucose monitoring devices and commercialization partner for Senseonics, have announced that the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio has begun offering the Eversense® CGM System to its Medicare enrollees effective early September, 2021.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 15,2021

Virta Health’s Diabetes Reversal Treatment Drives Savings of More Than $10k Per Patient Over Two Years, New Analysis Shows

Virta Health, the leader in type 2 diabetes reversal, saves payers $425 per patient per month (PPPM)—more than $10k over two years—according to a new internal analysis. The study, which is based on a methodology validated by independent actuarial firm Milliman, Inc., affirms Virta’s financial impact on employers, health plans, and patients struggling with the out-of-control costs of diabetes care.

View Analyst & Ambassador Comments
Go to original news
Sep 15,2021

ABBOTT DECLARES 391ST CONSECUTIVE QUARTERLY DIVIDEND

The board of directors of Abbott today declared a quarterly common dividend of 45 cents per share. This marks the 391st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2021, to shareholders of record at the close of business on Oct. 15, 2021. Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.

View Analyst & Ambassador Comments
Go to original news
Sep 15,2021

New LifeScan and Welldoc Partnership Brings Consumers an Evidence-Based Approach to Managing Diabetes and Other Chronic Conditions

LifeScan and Welldoc today announced a strategic partnership to incorporate Welldoc’s chronic condition platform, supporting hypertension, heart failure, diabetes, pre-diabetes and behavioral health, into the new OneTouch Solutions portal, designed to offer a choice of support, guidance and digital tools. OneTouch Solutions will be offered to consumers in the US starting this fall, and then offered to healthcare providers and payors as a reimbursed adjudicated option in early 2022.

COLLABORATION PARTNERSHIP

#product & service

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES